In conjunction with the Chicago Medical Society, The Chicago Urological Society Presents

UROTHELIAL CANCER

02/03/2016
University Club of Chicago

Keynote Address: Seth P. Lerner, MD
Bayor College of Medicine

Target Audience: Urologists
Educational Needs

The educational needs of health care providers managing patients with bladder cancer are complex and manifold. Emerging research and novel agents are changing patient care at a pace not seen in the last 30 years of bladder cancer care. Several distinct aspects of bladder cancer care remain challenging including management of BCG unresponsive disease, patients with T1 high grade bladder cancer, improving outcomes of radical cystectomy and treating metastatic disease. The purpose of this program is to provide urologists with an update regarding basic research and novel agents driving changes in patient care in management of high-risk non-muscle invasive bladder cancer and metastatic disease. Further, the program will provide an overview of advances in muscle-invasive bladder cancer and optimizing outcomes of radical cystectomy. The ultimate goal of this activity is to improve the armamentarium of the practicing urologist in caring for bladder cancer patients.

Desired Learning Outcomes

At the conclusion of this meeting, the attendee should be able to:

1. Describe novel genetic research findings in muscle-invasive bladder cancer, as well as potential impact of these pathways on patient care.
2. Recognize the new Paris classification system for urinary cytology and how it applies to management of bladder cancer patients.
3. Employ ERAS and care redesign in attempts to optimize surgical outcomes of radical cystectomy.
4. Assess controversies in management of patients with T1 high-grade bladder cancer and improve patient selection for early radical cystectomy versus continued intravesical therapy.
5. Improve understanding of use of immunotherapy checkpoint inhibitors in management of metastatic urothelial carcinoma.
6. Describe the association of cigarette smoking and bladder cancer, as well as the rationale and practice of treating tobacco dependence in the context of urological care.
7. Identify novel treatment options for BCG unresponsive patients with high-risk non-muscle invasive bladder cancer.

CME Information

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Chicago Medical Society and the Chicago Urological Society. The Chicago Medical Society is accredited by the ACCME to provide continuing medical education for physicians.

The Chicago Medical Society designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty List

Guliz Barkan, MD, FIAC, FABP
Associate Professor Pathology
Loyola Medicine
Maywood, IL

Dr. Barkan has disclosed that she does not have any relevant financial relationships with commercial interests.

Brian Helfand, MD, PhD
Adjunct Assistant Professor in Cell and Molecular Biology
Northwestern University
Chicago, IL

Dr. Helfand has disclosed that he does not have any relevant financial relationships with commercial interests.

Courtney M.P. Hollowell, MD, FACS
Chairman of the Division of Urology
Cook County Health and Hospitals System
Chicago, IL

Dr. Hollowell has disclosed that he does not have any relevant financial relationships with commercial interests.

Seth Lerner, MD
Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Director of Urologic Oncology, Director of the Multidisciplinary Bladder Cancer Program
Baylor College of Medicine
Houston, TX

Dr. Lerner has disclosed that he serves on the Board of Directors for BCAN, is a consultant for BioCancell and Vaxxion, Theracoat, Telesa and Kansas University, is an expert advisor for Sitka, Neucleixx and Taris, has received grants from Endo and FKD, and is the co-editor in chief for the Bladder Cancer Journal.

Joshua Meeks, MD, PhD
Assistant Professor of Urology
Northwestern University Feinberg School of Medicine
Chicago, IL

Dr. Meeks has disclosed that he does not have any relevant financial relationships with commercial interests.

Peter O'Donnell, MD
Assistant Professor of Medicine, Department of Medicine
The University of Chicago Medicine
Chicago, IL

Dr. O’Donnell has disclosed that he does not have any relevant financial relationships with commercial interests.

Marcus Quek, MD, PhD
Associate Professor, Medical Director, Urology
Loyola Medicine
Maywood, IL

Dr. Quek has disclosed that he does not have any relevant financial relationships with commercial interests.

Gary Steinberg, MD
Bruce and Beth White Family Professor, Professor of Surgery, Director, Urologic Oncology
The University of Chicago Medicine
Chicago, IL

Dr. Steinberg has disclosed that he is a scientific advisor for Cold Genesys, Heat Biologics, Photocure, Taris Biomedical, Roche Genentech and Telesa Therapeutics.
Wednesday, February 3, 2016
Program Chair: Norm Smith, MD

1:30 - 1:55 PM  The Bladder Cancer Genome Atlas: Is it a Game-Changer?
Brian Helfand, MD, PhD

1:55 - 2:20 PM  The Paris Classification of Urinary Cytology
Guliz Barkan, MD, FIAC, FABP

2:20 - 2:45 PM  UERAS and Care Redesign for Optimizing Patient Outcomes After Radical
Cystectomy
Joshua Meeks, MD, PhD

2:45 - 3:10 PM  Optimal Management of T1 High-grade Bladder Cancer
Marcus Quek, MD, FACS

3:10 - 3:30 PM  Comments and Questions
Norm Smith, MD
Seth Lerner, MD

3:30 - 3:45 PM  Break*

3:45 - 4:10 PM  Immunotherapy for Metastatic Urothelial Carcinoma
Peter O'Donnell, MD

4:10 - 4:35 PM  Bladder Cancer and an Effective Smoking Cessation Strategy in the Urology
Setting
Courtney M.P. Hollowell, MD, FACS

4:35 - 5:00 PM  Treatment Options for High-Risk BCG Unresponsive Non-muscle Invasive
Bladder Cancer
Gary Steinberg, MD

5:00 - 5:45 PM  Keynote Address: Advances in Management of Muscle-Invasive Bladder
Cancer
Seth Lerner, MD

5:45 - 7:00 PM  Cocktails and hors d'oeuvres with Exhibitors*

* No CME credits awarded
University Club of Chicago
76 E. Monroe Street, 2nd Floor
Chicago, Illinois

Parking
Valet parking is available at $25 per vehicle.
Self parking is available at the following garages:
• Grant Park East (Colombus/Michigan)
• Grant Park North (Madison/Michigan)
• Grant Park South (Jackson/Michigan)
• Inter Parking (55 E. Monroe)

Dress Code:
Please note that the University Club of Chicago has a dress code of business casual to business attire. No denim is permitted.

Exhibitors
The CUS would like to sincerely thank all of our Exhibitors for their participation in this event. Attendees will have the opportunity to meet with industry representatives in the designated Exhibitor area.

Astellas Oncology
Astellas Pharma US
Bayer Oncology
Coloplast
Dendreon Pharmaceuticals
Endo Pharmaceuticals
Ferring Pharmaceuticals
Genomic Health
Lumenis
Medivation
NeoTract, Inc.
Pacific Edge Diagnostics
Pfizer
TOLMAR Pharmaceuticals

CME Planning Committee
The following planning members of the Chicago Medical Society’s CME Subcommittee on Joint Providership have disclosed that they have no relevant financial relationships with commercial interests:

Michael Hanak, MD, FAA
Eric A. Eason, MD
Arjang Khorasani, MD
Alfonso Mejia II, MD
Vemuri S. Murthy, MD
Haydee Nascimento (Director of Education)

The following planning members of the Chicago Urological Society have disclosed that they have no relevant financial relationships with any commercial interests:

Norm Smith, MD, Course Director
Jessica Knight, Meeting Coordinator

Meeting Registration
Online: www.cuschicago.com
Phone: (312) 853-2053
Email: info@cuschicago.com

CUS Members....................................$0.00
CUS Emeritus Members....................$0.00
Non-Member Physicians................$200.00
Allied Health Professionals..............$65.00

The February 2016 Urothelial Cancer meeting will feature an extended cocktail hour with heavy hors d’oeuvres. No seated dinner will be served.